Exelixis, Inc.
210 East Grand Avenue
South San Francisco,
CA 94080
United States - Map
Phone: 650-837-7000
Fax: 650-837-8300
Website: http://www.exelixis.com
Exelixis, Inc., a biotechnology company, engages in developing small molecule therapies for the treatment of cancer in the United States. It focuses on developing and commercializing COMETRIQ (cabozantinib), an inhibitor of multiple receptor tyrosine kinases for the treatment of progressive, metastatic medullary thyroid cancer. COMETRIQ is also involved in various other cancer indications, including two ongoing Phase III pivotal trials in metastatic castration-resistant prostate cancer; and two additional Phase III pivotal trials in metastatic hepatocellular cancer and metastatic renal cell cancer. In addition, the company has a portfolio of other novel compounds that address serious unmet medical needs. Exelixis, Inc. has collaborations with Bristol-Myers Squibb Company, Sanofi, Genentech, Inc., GlaxoSmithKline, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California. Key Statistics
| |
| Exelixis, Inc.’s ISS Governance QuickScore as of May 1, 2013 is 4. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 5; Compensation: 4. | | Brought to you by Institutional Shareholder Services (ISS) |
| | Pay | Exercised | Dr. Stelios Papadopoulos Ph.D.,
65
Co-Founder, Chairman and Member of Audit Committee | 75.00K | N/A | Mr. Michael M. Morrissey Ph.D.,
52
Chief Exec. Officer, Pres and Director | 1.06M | 0.00 | Mr. Frank L. Karbe ,
44
Chief Financial Officer, Principal Accounting Officer and Exec. VP | 671.00K | 0.00 | Ms. Pamela A. Simonton J.D., LL.M,
63
Exec. VP and Gen. Counsel | 612.00K | 0.00 | Dr. Gisela M. Schwab M.D.,
56
Chief Medical Officer and Exec. VP | 707.00K | 0.00 |
|
| | Amounts are as of Dec 30, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year. | | Currency in USD. |
|
0.12%